AR125460A1 - Compuestos deuterados y agentes de imagen para la obtención de imágenes de la proteína huntingtina - Google Patents
Compuestos deuterados y agentes de imagen para la obtención de imágenes de la proteína huntingtinaInfo
- Publication number
- AR125460A1 AR125460A1 ARP220101094A ARP220101094A AR125460A1 AR 125460 A1 AR125460 A1 AR 125460A1 AR P220101094 A ARP220101094 A AR P220101094A AR P220101094 A ARP220101094 A AR P220101094A AR 125460 A1 AR125460 A1 AR 125460A1
- Authority
- AR
- Argentina
- Prior art keywords
- haloalkyl
- imaging
- deuterated
- alkyl
- haloalkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000012216 imaging agent Chemical class 0.000 title abstract 4
- 102000016252 Huntingtin Human genes 0.000 title 1
- 108050004784 Huntingtin Proteins 0.000 title 1
- 238000003384 imaging method Methods 0.000 title 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 230000004931 aggregating effect Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000004845 protein aggregation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En el presente documento se proporcionan ciertos compuestos y agentes de formación de imágenes útiles para detectar una enfermedad o condición asociada con la agregación de proteínas, composiciones de los mismos y métodos para su uso. Reivindicación 1: Un compuesto de fórmula (1) o un análogo enriquecido isotópicamente, sal farmacéuticamente aceptable, profármaco, tautómero, estereoisómero o una mezcla de estereoisómeros de los mismos, en donde: R¹ es alquilo C₁₋₆, alquenilo C₂₋₆, haloalquilo C₁₋₆, haloalquilo C₁₋₆ deuterado, alcoxi C₁₋₆, haloalcoxi C₁₋₆ deuterado o -O-alquileno-O-SO₂ -R⁵; R⁵ es arilo opcionalmente sustituido con alquilo; R² está ausente, es alquilo C₁₋₆, haloalquilo C₁₋₆, haloalquilo C₁₋₆ deuterado, haloalcoxi C₁₋₆ o haloalcoxi C₁₋₆ deuterado; R³ es halo, alquiloC₁₋₆ o haloalquilo C₁₋₆; y n es 0, 1 o 2. Reivindicación 19: Un agente de formación de imágenes que comprende el compuesto de la reivindicación 17 o 18, o un análogo enriquecido isotópicamente, una sal farmacéuticamente aceptable, un profármaco, un tautómero, un estereoisómero o una mezcla de estereoisómeros de los mismos. Reivindicación 20: Un método para detectar la presencia o ausencia de una proteína susceptible de agregación en un individuo que comprende administrar una cantidad efectiva de un compuesto de la reivindicación 17 o 18, o un agente de formación de imágenes de la reivindicación 19 a un individuo, y generar una imagen de una parte del cuerpo o área del cuerpo del individuo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163180608P | 2021-04-27 | 2021-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125460A1 true AR125460A1 (es) | 2023-07-19 |
Family
ID=81654542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101094A AR125460A1 (es) | 2021-04-27 | 2022-04-27 | Compuestos deuterados y agentes de imagen para la obtención de imágenes de la proteína huntingtina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220372045A1 (es) |
| EP (1) | EP4329826A1 (es) |
| JP (1) | JP2024516393A (es) |
| KR (1) | KR20240001208A (es) |
| CN (1) | CN117545512A (es) |
| AR (1) | AR125460A1 (es) |
| AU (1) | AU2022264490A1 (es) |
| BR (1) | BR112023022442A2 (es) |
| CA (1) | CA3216753A1 (es) |
| IL (1) | IL308060A (es) |
| MX (1) | MX2023012652A (es) |
| TW (1) | TW202309050A (es) |
| WO (1) | WO2022232121A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211778T1 (hr) | 2014-08-29 | 2022-03-18 | Chdi Foundation, Inc. | Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina |
| JP2022521431A (ja) | 2019-02-25 | 2022-04-07 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用 |
-
2022
- 2022-04-26 WO PCT/US2022/026313 patent/WO2022232121A1/en active Application Filing
- 2022-04-26 AU AU2022264490A patent/AU2022264490A1/en active Pending
- 2022-04-26 TW TW111115848A patent/TW202309050A/zh unknown
- 2022-04-26 KR KR1020237040619A patent/KR20240001208A/ko unknown
- 2022-04-26 BR BR112023022442A patent/BR112023022442A2/pt unknown
- 2022-04-26 JP JP2023565474A patent/JP2024516393A/ja active Pending
- 2022-04-26 CN CN202280044438.2A patent/CN117545512A/zh active Pending
- 2022-04-26 CA CA3216753A patent/CA3216753A1/en active Pending
- 2022-04-26 US US17/729,881 patent/US20220372045A1/en active Pending
- 2022-04-26 EP EP22723880.5A patent/EP4329826A1/en active Pending
- 2022-04-26 IL IL308060A patent/IL308060A/en unknown
- 2022-04-26 MX MX2023012652A patent/MX2023012652A/es unknown
- 2022-04-27 AR ARP220101094A patent/AR125460A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023022442A2 (pt) | 2024-03-12 |
| EP4329826A1 (en) | 2024-03-06 |
| MX2023012652A (es) | 2024-01-08 |
| IL308060A (en) | 2023-12-01 |
| WO2022232121A1 (en) | 2022-11-03 |
| CN117545512A (zh) | 2024-02-09 |
| TW202309050A (zh) | 2023-03-01 |
| JP2024516393A (ja) | 2024-04-15 |
| US20220372045A1 (en) | 2022-11-24 |
| CA3216753A1 (en) | 2022-11-03 |
| AU2022264490A1 (en) | 2023-11-09 |
| KR20240001208A (ko) | 2024-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| UY39029A (es) | Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2 | |
| AR076949A1 (es) | Derivados de 1h-imidazo-(4,5-c)-quinolinona | |
| PE20210046A1 (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil peptido | |
| ES2215893T3 (es) | Derivados de beta-aminoacidos como inhibidores de metaloproteasas de matriz y tnf-alfa. | |
| AR066882A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| AR090041A1 (es) | Aril dihidropiridinona y piperidinona como inhibidores de mgat2 | |
| AR076984A1 (es) | Derivados de pirazol oxadiazol | |
| AR074148A1 (es) | Derivados de corticoesteroides beta agonistas fosforilados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades del aparato respiratorio | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| AR067454A1 (es) | Derivados de indano- amina, su preparacion y uso como medicamentos | |
| CO6361996A2 (es) | 5- (2-{ [6- (2, 2-difluoro-2-feniletoxi) hexil] amino} -1-hidroxietil) -8-hidroxiquinolin-2 (ih)-ona y su uso en el tratamiento de enfermedades pulmonares | |
| AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| KR900004658A (ko) | 이치환 벤질아민, 그의 제조방법, 약제로서의 그의 용도 및 그의 합성 약제 | |
| CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| AR127501A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| AR125460A1 (es) | Compuestos deuterados y agentes de imagen para la obtención de imágenes de la proteína huntingtina | |
| UY28688A1 (es) | Derivados de amida | |
| AR123049A1 (es) | Compuestos terapéuticos y modos de uso | |
| AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
| AR050101A1 (es) | Oxazolidinonas que contienen oxindoles como agentes antibacterianos. | |
| ES2041815T3 (es) | Un procedimiento para la obtencion de derivados de ornitina 5-sustituidos. |